[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharmaceutical and Healthcare Industry in Brazil - Forecast and Analysis 2021

August 2021 | 140 pages | ID: PCF2A69BE878EN
Aruvian's R'search

US$ 800.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Brazil has been one of the worst COVID-affected countries in the world. The Brazilian government has been severely criticized for its handling of the pandemic. In March 2021, Brazilians began receiving the first dose of the vaccine.

The pharmaceutical and healthcare market in Brazil is the biggest in Latin America. The Brazilian pharmaceutical market is also one of the most attractive markets in the Americas regions. With a high burden of diseases, the pharmaceutical sector in the country is poised for fast growth despite the pandemic. The industry is dominated by generic products.

Though there will be some short-term impacts felt on the market from the COVID-19 pandemic, the expenditure on healthcare and pharmaceuticals will continue to increase in the coming years. With many changes and a new business strategy in place, the Brazilian healthcare industry is today one of the most attractive globally, drawing investments from all over the world.

Aruvian Research presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of Brazil in its research report Pharmaceutical and Healthcare Industry in Brazil – Forecast and Analysis 2021. The report covers the following data:
  • A brief overview of the pharmaceutical and healthcare industry in the Americas and a snapshot of the sector across some leading and underperforming markets of the region.
  • An in-depth coverage of the pharmaceutical and healthcare industry in Brazil by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for medical research and clinical trials in Brazil.
  • A SWOT analysis of the Brazilian pharmaceutical and healthcare industry.
  • A Porter's Five Forces Strategic Analysis of the Brazilian pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.
  • We take an up-close view of the regulatory framework governing the Brazilian pharmaceutical and healthcare industry, and the challenges being faced in terms of intellectual property rights.
  • Competition in the industry, along with an in-depth analysis of the both the domestic and multinational players in the sector like Ach?, Crist?lia, Eurofarma, EMS, Medley, GlaxoSmithKline, Roche, Sanofi, and many others is included.
A detailed forecast of the Brazilian pharmaceutical and healthcare industry by segments completes this comprehensive analysis.
A. EXECUTIVE SUMMARY

B. INDUSTRY DEFINITION

C. BRIEF VIEW OF THE AMERICAS PHARMACEUTICAL & HEALTHCARE SECTOR

D. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN BRAZIL

D.1 Impact of COVID-19 on the Industry
D.2 Pharmaceutical Sector Analysis
D.3 Healthcare Sector Analysis
D.4 Market for Prescription Drugs
D.5 Market for Patented Drugs
D.6 Market for OTC Medicines
D.7 Market for Generic Drugs
D.8 Medical Research & Clinical Trials in Brazil

E. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN BRAZIL: SWOT ANALYSIS

E.1 Strengths to Build Upon
E.2 Weaknesses to Overcome
E.2 Opportunities to Exploit
E.4 Threats to Overcome

F. BRAZIL PHARMACEUTICAL INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS

F.1 Overview
F.2 Bargaining Power of Buyers
F.3 Bargaining Power of Suppliers
F.4 Competitive Rivalry in the Industry
F.5 Threat of New Entrants
F.6 Threat of Substitutes

G. CHRONIC MEDICAL CONDITIONS IN BRAZIL

G.1 Overview
G.2 Cancer
G.3 Cardiovascular Diseases
G.4 Diabetes

H. REGULATORY FRAMEWORK OF THE INDUSTRY

H.1 Overview
H.2 Regulations Governing Generic Drugs
H.3 Challenges with Intellectual Property Rights
H.4 TRIPS & Compulsory Licensing
H.5 Challenges with Counterfeit Medications
H.6 Pricing & Reimbursement Regime
H.7 Regulations Governing Manufacturing Standards
H.8 Regulations Governing Marketing of Pharmaceuticals

I. IMPORT/EXPORT OF PHARMACEUTICALS IN BRAZIL

J. COMPETITION IN THE INDUSTRY

J.1 Competitive Landscape
J.2 Competition in Generic Drugs
J.3 Competition in the Pharmacy Sector
J.4 Competition in Drug Distribution

K. FORECAST: PHARMACEUTICAL & HEALTHCARE INDUSTRY IN BRAZIL

K.1 Outlook of the Pharmaceutical Industry
K.2 Outlook of the Healthcare Industry
K.3 Outlook for Prescription Drugs Sector
K.4 Outlook for Patented Drugs Market
K.5 Outlook for OTC Medicine Market
K.6 Outlook for the Generic Drugs Market

L. MAJOR INDUSTRY PLAYERS

L.1 Ach? Laboratorios Farmaceuticos SA
  L.1.1 Corporate Analysis
  L.1.2 Business Segment Analysis
  L.1.3 SWOT Analysis
L.2 Cristalia Produtos Quimicos Farmaceuticos Ltda (Crist?lia)
  L.2.1 Corporate Analysis
  L.2.2 Business Segment Analysis
  L.2.3 SWOT Analysis
L.3 EMS Sigma
  L.3.1 Corporate Analysis
  L.3.2 Business Segment Analysis
  L.3.3 SWOT Analysis
L.4 Eurofarma
  L.4.1 Corporate Analysis
  L.4.2 Business Segment Analysis
  L.4.3 SWOT Analysis
L.5 GlaxoSmithKline
  L.5.1 Corporate Analysis
  L.5.2 Business Segment Analysis
  L.5.3 SWOT Analysis
L.6 Medley Ind?stria Farmac?utica Ltda
  L.6.1 Corporate Analysis
  L.6.2 Business Segment Analysis
  L.6.3 SWOT Analysis
L.7 Merck & Co. Inc. (MSD)
  L.7.1 Corporate Analysis
  L.7.2 Business Segment Analysis
  L.7.3 SWOT Analysis
L.8 Novartis
  L.8.1 Corporate Analysis
  L.8.2 Business Segment Analysis
  L.8.3 SWOT Analysis
L.9 Pfizer
  L.9.1 Corporate Analysis
  L.9.2 Business Segment Analysis
  L.9.3 SWOT Analysis
L.10 Roche
  L.10.1 Corporate Analysis
  L.10.2 Business Segment Analysis
  L.10.3 SWOT Analysis
L.11 Sanofi SA
  L.11.1 Corporate Analysis
  L.11.2 Business Segment Analysis
  L.11.3 SWOT Analysis

M. GLOSSARY OF TERMS

N. RESEARCH METHODOLOGY

O. DISCLAIMER

LIST OF FIGURES

Figure 1: Growth of the Pharmaceutical Sales in Brazil, 2016-2030
Figure 2: Clinical Trial Registrations in Brazil, 2016-2019
Figure 3: Porter's Five Forces Analysis of the Brazilian Pharmaceutical Industry
Figure 4: Bargaining Power of Buyers in the Brazilian Pharmaceutical Industry
Figure 5: Bargaining Power of Suppliers in the Brazilian Pharmaceutical Industry
Figure 6: Competitive Rivalry in the Brazilian Pharmaceutical Industry
Figure 7: Threat of New Entrants to the Brazilian Pharmaceutical Industry
Figure 8: Threat of Substitutes to the Brazilian Pharmaceutical Industry
Figure 9: Import-Export of Pharmaceuticals in Brazil (in BRL Million), 2016-2025
Figure 10: Expenditure on Healthcare in Brazil, 2016-2030
Figure 11: Forecast of the Prescription Drug Market in Brazil, 2016-2030
Figure 12: Forecast of the Patented Drugs Sector in Brazil, 2016-2030
Figure 13: Forecast of the OTC Medicine Market in Brazil, 2016-2030
Figure 14: Forecast of the Generic Drug Market in Brazil, 2016-2030

LIST OF TABLES

Table 1: Growth of the Pharmaceutical Sales in Brazil, 2017-2025
Table 2: Healthcare Resources in Brazil, 2015-2020
Table 3: Inpatient/Outpatient Statistics in Brazil, 2015-2020
Table 4: Personnel Employed in the Healthcare Sector in Brazil, 2015-2020
Table 5: Import-Export of Pharmaceuticals in Brazil (in BRL Million), 2019-2025
Table 6: Import-Export of Pharmaceuticals in Brazil (in USD Million), 2019-2025
Table 7: Statistics of the Pharmaceutical & Healthcare Industry in Brazil, 2019-2025
Table 8: Expenditure on Healthcare in Brazil, 2017-2025
Table 9: Government Expenditure on Healthcare in Brazil, 2017-2025
Table 10: Healthcare Expenditure by Private Sector on Healthcare in Brazil, 2017-2025
Table 11: Forecast of the Prescription Drug Market in Brazil, 2017-2025
Table 12: Forecast of the Patented Drugs Sector in Brazil, 2017-2025
Table 13: Forecast of the OTC Medicine Market in Brazil, 2017-2025
Table 14: Forecast of the Generic Drug Market in Brazil, 2017-2025


More Publications